131 related articles for article (PubMed ID: 23167412)
1. Involvement of FoxM1 in non-small cell lung cancer recurrence.
Xu N; Wu SD; Wang H; Wang Q; Bai CX
Asian Pac J Cancer Prev; 2012; 13(9):4739-43. PubMed ID: 23167412
[TBL] [Abstract][Full Text] [Related]
2. [Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].
Liu YQ; Guo RH; Liu LK; Gao W; Zhu CJ; Wei J; Shu YQ
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):426-30. PubMed ID: 21875482
[TBL] [Abstract][Full Text] [Related]
3. FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis.
Xu N; Jia D; Chen W; Wang H; Liu F; Ge H; Zhu X; Song Y; Zhang X; Zhang D; Ge D; Bai C
PLoS One; 2013; 8(3):e59412. PubMed ID: 23536876
[TBL] [Abstract][Full Text] [Related]
4. Potentiality of forkhead box Q1 as a biomarker for monitoring tumor features and predicting prognosis in non-small cell lung cancer.
Li L; Xu B; Zhang H; Wu J; Song Q; Yu J
J Clin Lab Anal; 2020 Jan; 34(1):e23031. PubMed ID: 31713908
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer.
Kong FF; Qu ZQ; Yuan HH; Wang JY; Zhao M; Guo YH; Shi J; Gong XD; Zhu YL; Liu F; Zhang WY; Jiang B
Oncol Rep; 2014 Jun; 31(6):2660-8. PubMed ID: 24715097
[TBL] [Abstract][Full Text] [Related]
6. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance.
Yang DK; Son CH; Lee SK; Choi PJ; Lee KE; Roh MS
Hum Pathol; 2009 Apr; 40(4):464-70. PubMed ID: 19121844
[TBL] [Abstract][Full Text] [Related]
8. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
[TBL] [Abstract][Full Text] [Related]
9. MnSOD promotes tumor invasion via upregulation of FoxM1-MMP2 axis and related with poor survival and relapse in lung adenocarcinomas.
Chen PM; Wu TC; Shieh SH; Wu YH; Li MC; Sheu GT; Cheng YW; Chen CY; Lee H
Mol Cancer Res; 2013 Mar; 11(3):261-71. PubMed ID: 23271813
[TBL] [Abstract][Full Text] [Related]
10. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
12. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
[TBL] [Abstract][Full Text] [Related]
13. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.
Zhang H; Duan CJ; Chen W; Wang SQ; Zhang SK; Dong S; Cheng YD; Zhang CF
Asian Pac J Cancer Prev; 2012; 13(5):2355-62. PubMed ID: 22901222
[TBL] [Abstract][Full Text] [Related]
15. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
Wang X; Du Z; Li L; Shi M; Yu Y
Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
[TBL] [Abstract][Full Text] [Related]
16. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
Xu XY; Lin N; Li YM; Zhi C; Shen H
Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
[TBL] [Abstract][Full Text] [Related]
17. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer.
Hamanaka R; Yokose T; Sakuma Y; Tsuboi M; Ito H; Nakayama H; Yamada K; Masuda R; Iwazaki M
Diagn Pathol; 2015 Apr; 10():17. PubMed ID: 25884820
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.
Jiang W; Pang XG; Wang Q; Shen YX; Chen XK; Xi JJ
Clin Lung Cancer; 2012 Jul; 13(4):280-7. PubMed ID: 22178381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
